The Current Ratio as of June 2025 (TTM) for Belite Bio, Inc (BLTE) is 24.31

According to Belite Bio, Inc’s latest financial reports and current stock price. The company's current Current Ratio is 24.31. This represents a change of 30.33% compared to the average of 18.65 of the last 4 quarters.

Belite Bio, Inc (BLTE) Historical Current Ratio (quarterly & annually)

How has BLTE Current Ratio performed in the past?

The mean historical Current Ratio of Belite Bio, Inc over the last ten years is 21.30. The current 24.31 Current Ratio has changed 11.32% with respect to the historical average. Over the past ten years (40 quarters), BLTE's Current Ratio was at its highest in in the June 2022 quarter at 35.01K. The Current Ratio was at its lowest in in the March 2022 quarter at 0.

Belite Bio, Inc (BLTE) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Belite Bio, Inc Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Belite Bio, Inc (BLTE) Average Current Ratio

How has BLTE Current Ratio performed in the past?

The current Current Ratio of Belite Bio, Inc (BLTE) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Belite Bio, Inc (BLTE) Current Ratio vs. Peers

How is BLTE’s Current Ratio compared to its peers?

Belite Bio, Inc’s Current Ratio is less than Anebulo Pharmaceuticals, Inc. (32.29), less than Mineralys Therapeutics, Inc. (26.48), greater than AN2 Therapeutics, Inc. (8.68), greater than Aerovate Therapeutics, Inc. (5.81), greater than Adagene Inc. (2.30), greater than Larimar Therapeutics, Inc. (7.48), greater than Immuneering Corporation (7.48), greater than Centessa Pharmaceuticals plc (14.37), greater than Celcuity Inc. (6.61), greater than Ikena Oncology, Inc. (13.31), greater than Molecular Partners AG (14.31), greater than PMV Pharmaceuticals, Inc. (16.75), greater than Monte Rosa Therapeutics, Inc. (5.61), greater than Entrada Therapeutics, Inc. (21.88), greater than Vigil Neuroscience, Inc. (2.97), greater than Acrivon Therapeutics, Inc. Common Stock (11.17), greater than AnaptysBio, Inc. (8.25), greater than Galecto, Inc. (9.62), greater than Aadi Bioscience, Inc. (18.95), greater than Aligos Therapeutics, Inc. (7.56),

Build a custom stock screener for Belite Bio, Inc (BLTE) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Belite Bio, Inc using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Belite Bio, Inc (BLTE) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Belite Bio, Inc or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.